Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Non-inferiority Study to Evaluate Injectable Albumin-bound Paclitaxel Versus Docetaxel for the Adjuvant Treatment of Breast Cancer

NCT05420467 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT05420467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05420467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Non-inferiority Study to Evaluate Injectable Albumin-bound Paclitaxel Versus Docetaxel for the Adjuvant Treatment of Breast Cancer
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Phase 4
Overall status
Recruiting
Start date
July 10, 2022
Completion date
December 20, 2027
Enrollment
2,413 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer